Logo
Contact    |    Site Map    |    Careers

 

The Leukemia & Lymphoma Society and Acetylon Pharmaceuticals Partner to Advance the Clinical Development of Acetylon's ricolinostat (ACY-1215) Drug Candidate for Multiple Myeloma

Their funding is helping to support the first clinical trial of ricolinostat

In May 2011, The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals announced a newly formed business alliance whereby both entities will jointly support a Phase I/II clinical trial of Acetylon’s oral selective HDAC6 inhibitor drug candidate, ricolinostat, in multiple myeloma.

LLS has since committed to provide up to $5.63 million in milestone-tranched funding to Acetylon, and a joint clinical oversight committee has been formed.

Please read the press release for more details.